Report Overview

The global Alport Syndrome market size stood at around USD 0.33 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Alport syndrome is a rare genetic condition characterized by kidney disease, hearing loss, and eye abnormalities. This condition is caused by mutation in the genes COL4A3, COL4A4, and COL4A5, which are involved in the production of proteins such as type IV collagen. Patients suffering from Alport syndrome suffer from progressive loss of kidney function. Presence of blood in urine indicates abnormal functioning of the kidneys. A number of patients suffering from Alport syndrome develop high levels of proteins in the urine. As the condition progresses, the kidney function deteriorates leading to end-stage renal disease (ESRD)



 

Market Drivers and restraints

Rise in prevalence of genetic disorders is likely to augment the global Alport syndrome market. There is no cure for this syndrome. Hence, availability of drugs for the management of its symptoms such as high blood pressure is projected to boost the growth of the global market. Demand for genetic testing as an effective diagnostic procedure for Alport syndrome is anticipated to drive the global Alport syndrome market. Moreover, skin biopsy and kidney biopsy are used for diagnosis of the early symptoms of Alport syndrome and faster adoption of these diagnostic techniques is a major factor propelling the global market. High investments by the key players and initiatives by governments for research and development of drugs for managing Alport syndrome and its symptoms are likely to propel the global Alport syndrome market. Hence, faster adoption and availability of diagnostic tests across the globe are anticipated to augment the global Alport syndrome market. However, low awareness about the syndrome and its lower diagnosis rates in underdeveloped countries act as major restraints of the global Alport syndrome market